Last reviewed · How we verify
Lyrica (pregabalin)
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury), Partial-onset seizures (adjunctive therapy), Fibromyalgia.
At a glance
| Generic name | Lyrica (pregabalin) |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Gabapentinoid; anticonvulsant; anxiolytic |
| Target | Alpha-2-delta subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology; Pain Management; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By binding to calcium channel subunits on nerve endings, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, norepinephrine, and substance P. This dampens neuronal hyperexcitability and pain signal transmission. The drug is thought to work through multiple mechanisms including modulation of neurotransmitter release and stabilization of neuronal activity.
Approved indications
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury)
- Partial-onset seizures (adjunctive therapy)
- Fibromyalgia
- Generalized anxiety disorder
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema (peripheral)
- Weight gain
- Blurred vision
- Ataxia
Key clinical trials
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (NA)
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver (PHASE4)
- Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain (PHASE4)
- Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients (NA)
- Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial (NA)
- The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia (NA)
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lyrica (pregabalin) CI brief — competitive landscape report
- Lyrica (pregabalin) updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI